| Market Cap | 7.18M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -13.06M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -45.00% |
| Sales | 155k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -69.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -98.00% |
| Recommedations | - | Quick Ratio | 0.02 | Shares Outstanding | 13.63M | 52W Low Chg | 12.00% |
| Insider Own | 18.79% | ROA | -113.66% | Shares Float | 11.12M | Beta | 1.99 |
| Inst Own | 2.27% | ROE | - | Shares Shorted/Prior | 191.75K/277.77K | Price | 0.15 |
| Gross Margin | -5.16% | Profit Margin | - | Avg. Volume | 2,926,850 | Target Price | - |
| Oper. Margin | -5,675.00% | Earnings Date | Aug 19 | Volume | 4,587,878 | Change | -14.34% |
FOXO Technologies Inc. develops epigenetic biomarkers technology solutions in the United States. The company applies automated machine learning and artificial intelligence (AI) technologies to discover epigenetic biomarkers of human health, wellness, and aging. It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and Bioinformatics services that provides data solutions using AI and machine learning for data analysis and processing, and quality checking for academia, healthcare, government, and pharmaceutical research customers. FOXO Technologies Inc. was founded in 2020 and is based in Minneapolis, Minnesota.